QCG
KERX

Quadrant Capital Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Quadrant Capital Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-49
Closed – – 2110
2015
Q4 		$0 Sell
49
-128
-72% -$608 ﹤0.01% 1779
2015
Q3 		$0 Hold
177
– – ﹤0.01% 1437
2015
Q2 		$1K Buy
+177
New +$1.9K ﹤0.01% 1125

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Quadrant Capital Group's KERX Position: Q1 2016 in Review

Quadrant Capital Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2016, closing a stake of 49 shares.

Quadrant Capital Group first reported a position in KERX in Q2 2015 and held it in 3 quarters. The position peaked at $1K in Q2 2015. 130 funds tracked by Wall St. Rank hold KERX as of Q1 2016.

  • Quadrant Capital Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2016 after selling out during the quarter.
  • Quadrant Capital Group sold 49 Keryx Biopharmaceuticals Inc shares in Q1 2016.
  • Quadrant Capital Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 3 quarters.
  • Quadrant Capital Group's Keryx Biopharmaceuticals Inc position peaked at $1K in Q2 2015.
  • 130 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2016.

Based on Quadrant Capital Group's 13F filing for Q1 2016, filed 27 Apr 2016.